Advanced Solutions
for Advanced Pathology
CD61 (2f2)
Mouse Monoclonal Antibody
Cat. No. Description
Volume
45135 IMPATH CD61 RTU M (2f2)
50 Tests
44247 CD61 RTU M (2F2)
7 ml Ready To Use
44515 CD61 0,1 M (2F2)
100 µl liquid Concentrated
44516 CD61 1 M (2F2)
1 ml liquid Concentrated
Product Specifications
Designation
IVD
Reactivity
Paraffin
Visualization
Cytoplasmic
Control
Bone Marrow
Stability
Up to 36 mo. at 2-8°C
Isotype
IgG
1
Manual Protocol*
• Pretreatment: Heat Induced Epitope
Retrieval (HIER)
• Primary Antibody Incubation Time:
10-30min @ 25-37°C
• 2-step polymer detection
*Please refer to product insert for complete protocol.
ImPath Protocol*
• Dewax: Dewax Solution 2 (DS2)
• Pretreatment: Retrieval Solution pH 9.0
(TR1) 32min @ 98-103°C
• Primary Antibody Incubation Time:
10-90min @ 25-37°C
• HRP Polymer (Universal) or AP Polymer
(Universal) for 12 min
*Please refer to product insert for complete protocol.
Product Description
CD61 is the human integrin beta chain beta 3 protein (ITGB3). Integrins are integral cell-surface proteins composed of an alpha chain and a beta
chain. A given chain may combine with multiple partners resulting in different integrins. Integrin beta 3 is found along with the alpha IIb chain in
platelets. Integrins are known to participate in cell adhesion as well as cell-surface mediated signaling. The integrin beta 3 chain of the vitronectin
receptor and GPIIb/IIIa complex is a 90-110 kDa glycoprotein polypeptide which is expressed on platelets, megakaryocytes, macrophages,
osteoclasts, and synovial lining cells. Integrin alpha-IIb/beta-3 recognizes the sequence H-H-L-G-G-G-A-K-Q-A-G-D-V in fibrinogen gamma
chain. Following activation, integrin alpha-IIb/beta-3 brings about platelet/platelet interaction through binding of soluble fibrinogen. This step
leads to rapid platelet aggregation which physically plugs ruptured endothelial surface. In case of HIV-1 infection, the interaction with extracellular
viral Tat protein seems to enhance angiogenesis in Kaposi’s sarcoma lesions.
This antibody is useful in evaluating the number of megakaryocytes, size, nuclear lobation, and the presence of obviously abnormal forms and
micromegakaryocytes in myelodysplastic syndrome, acute myeloid leukemia with multilineage dysplasia, acute megakaryoblastic leukemia, and
myeloproliferative neoplasms.
Acute Myeloid Leukemia
CD61
MPO CD68 Factor VIII Lysozyme BOB.1 Oct-2 Glyco-
phorin A CD34 CD138
Acute Myeloid, M0
-
-
-
-
+
-
-
-
+
+
Acute Myeloid, M1&2
-
+
+
-
+
-
+
+
Promyelocytic, M3
-
+
-
-
-
+
+
-
-
Myelomonocytic, M4
-
+
+
-
+
-
+
-
+
Monoblastic, M5
-
+
+
-
+
-
+
-
-/+
Acute Erythroid, M6
-
+
-
-
-
-
+
-/+
+
Megakaryoblastic, M7
+
-
-
+
+/-
-
-
-
-
Reference
1. Thiele J, et al. Eur J Haematol. 1990; 44:63-70.
2. Thiele J, et al. Virchows Archiv B Cell Pathol. 1990; 58:295-302.
3. Goldman BI, et al. Modern Pathology. 2001; 14:589-594.
4. Fox SB, et al. 1990 Jul; 17(1):69-74.
5. Duperray A, et al. Blood. 1989 Oct; 74(5):1603-11.
6. Campana D, et al. Leukemia. 1990 Sep; 4(9):620-4.
7. Thiele J, et al. Anal Quant Histol. 1990 Aug; 12(4):285-9.
75
